Quantitative EEG analysis in post-traumatic anosmia

Many objective and quantitative methods have been developed to create a procedure or a device to prove, describe and quantify olfactory deficit and anosmia, especially after a head trauma. Electrophysiological testing throughout olfactoelectroencephalography (olfactoEEG) is based on brain activity desynchronisation, and on the subsequent disappearance of alpha activity on the posterior regions after an olfactory stimulus. Yet traditional evaluation of EEG can be difficult, because of little or hardly detectable alpha activity on the posterior regions ('alpha rare'). The aim of this study was to evaluate the Olfactory Stop Reaction (OSR) by means of frequency band power calculation and subsequent topographical mapping in patients with post-traumatic anosmia, who presented 'alpha rare' EEG. Twenty-five consecutive patients, affected by anosmia caused by head trauma, were submitted to an EEG recording with olfactory stimulation. After signal processing and analysis, an Olfactory Stop Reaction was detected in 17 out of 25 patients; moreover, in these patients we detected a significant decrease in alpha band power in the occipital regions and an increase in theta band power on midline frontal and central regions after olfactory stimulation. In the remaining eight patients, no significant variation in band power was observed. In conclusion, an objective evaluation of the olfactory function with this method of automatic EEG signal analysis allows the limits given by psychophysical methods and traditional EEG to be overcome and attempts to fulfil the requirements for standardization of olfactory function evalution

PREVALENCE OF RESTLESS LEGS SYNDROME IN PATIENTS WITH RESISTANT HYPERTENSION: A CROSS-SECTIONAL, BI-CENTRIC COHORT STUDY

Objective: Though obstructive sleep apnea syndrome (OSAS) is common in patients with resistant hypertension (RH), the prevalence of other sleep disorders, such as restless legs syndrome (RLS) is unknown. We aimend at investigating the prevalence of OSAS and RLS in a cohort of patients with RH recruited in two centres. Design and method: By using the ESC/ESH definition we consecutively recruited 63 patients with RH (age 63 ± 12 years, BMI 32 ± 6 kg/mq, 24% women, 31% patients with previous CV events, 31% diabetic), undergoing a polisomnographic study. RLS rating scale, Epworth Sleepiness Scale (ESS), past medical history and office BP were obtained. Sleep stages were scored according to 2007 AASM modified criteria. Results: Moderate-severe OSAS (AHI>15/h) was diagnosed in 34 RH patients (54%), RLS in 26 (41%): 13 patients presented both conditions. Only 16 patients (25%) had neither OSAS nor RLS. Periodic limb movements (PLM Index>15/h) were present in 31% of the studied population. OSAS+RLS- and OSAS+RLS+ patients were older than OSAS-RLS- and OSAS-RLS+. None among OSAS-RLS- had diabetes. OSAS+RLS- patients had a reduced total sleep time, sleep and REM latency and sleep efficiency in comparison to OSAS-RLS-. Conversely, slow wave sleep was reduced only in OSAS+RLS+. PLM index was increased in OSAS-RLS+ [18 (0–36)] but not in OSAS+RLS+ [2 (0–25), p < 0.05]. Conclusions: OSAS and RLS are common in RH patients, often co-occurring. BMI or daily sleepiness are not useful to identify RH patients with sleep disorders, suggesting that all RH patients should undergo polisomnography. Diabetes seems to be a feature of RH patients with sleep disorders. When coexisting with OSAS, RLS is not associated with PLM, suggesting a different pathophysiology. However, the presence of OSAS together with RLS is associated with shorter slow wave sleep, a phenomenon that can possibly lead to severe cardiovascular and cognitive complications in this subgroup

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

Background Complement is likely to have a role in refractory generalised myasthenia gravis, but no approved therapies specifically target this system. Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis. We further assessed the efficacy and safety of eculizumab in this patient population in a phase 3 trial. Methods We did a phase 3, randomised, double-blind, placebo-controlled, multicentre study (REGAIN) in 76 hospitals and specialised clinics in 17 countries across North America, Latin America, Europe, and Asia. Eligible patients were aged at least 18 years, with a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of 6 or more, Myasthenia Gravis Foundation of America (MGFA) class II\ue2\u80\u93IV disease, vaccination against Neisseria meningitides, and previous treatment with at least two immunosuppressive therapies or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 months without symptom control. Patients with a history of thymoma or thymic neoplasms, thymectomy within 12 months before screening, or use of intravenous immunoglobulin or plasma exchange within 4 weeks before randomisation, or rituximab within 6 months before screening, were excluded. We randomly assigned participants (1:1) to either intravenous eculizumab or intravenous matched placebo for 26 weeks. Dosing for eculizumab was 900 mg on day 1 and at weeks 1, 2, and 3; 1200 mg at week 4; and 1200 mg given every second week thereafter as maintenance dosing. Randomisation was done centrally with an interactive voice or web-response system with patients stratified to one of four groups based on MGFA disease classification. Where possible, patients were maintained on existing myasthenia gravis therapies and rescue medication was allowed at the study physician's discretion. Patients, investigators, staff, and outcome assessors were masked to treatment assignment. The primary efficacy endpoint was the change from baseline to week 26 in MG-ADL total score measured by worst-rank ANCOVA. The efficacy population set was defined as all patients randomly assigned to treatment groups who received at least one dose of study drug, had a valid baseline MG-ADL assessment, and at least one post-baseline MG-ADL assessment. The safety analyses included all randomly assigned patients who received eculizumab or placebo. This trial is registered with ClinicalTrials.gov, number NCT01997229. Findings Between April 30, 2014, and Feb 19, 2016, we randomly assigned and treated 125 patients, 62 with eculizumab and 63 with placebo. The primary analysis showed no significant difference between eculizumab and placebo (least-squares mean rank 56\uc2\ub76 [SEM 4\uc2\ub75] vs 68\uc2\ub73 [4\uc2\ub75]; rank-based treatment difference \ue2\u88\u9211\uc2\ub77, 95% CI \ue2\u88\u9224\uc2\ub73 to 0\uc2\ub796; p=0\uc2\ub70698). No deaths or cases of meningococcal infection occurred during the study. The most common adverse events in both groups were headache and upper respiratory tract infection (ten [16%] for both events in the eculizumab group and 12 [19%] for both in the placebo group). Myasthenia gravis exacerbations were reported by six (10%) patients in the eculizumab group and 15 (24%) in the placebo group. Six (10%) patients in the eculizumab group and 12 (19%) in the placebo group required rescue therapy. Interpretation The change in the MG-ADL score was not statistically significant between eculizumab and placebo, as measured by the worst-rank analysis. Eculizumab was well tolerated. The use of a worst-rank analytical approach proved to be an important limitation of this study since the secondary and sensitivity analyses results were inconsistent with the primary endpoint result; further research into the role of complement is needed. Funding Alexion Pharmaceuticals